Answers are grounded in this paper and cite their sources.
This article discusses the patent strategy underlying the world's best selling drug, AbbVie's Humira®. Despite a non-optimal starting position, AbbVie has established an extensive portfolio to fend off biosimilar competition. This article is the first part of a trilogy that discusses IP issues related to anti-Tumor Necrosis factor α (TNFα) biologics.
No takes yet. Share an insight, caveat, or question.
Ulrich Storz (2016) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: